title: Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients.
abstract: Ten severely immunocompromised HIV-HCV co-infected patients were enrolled in a quantifiable HCV-RNA assay. Serum alanine aminotransferase, HCV-RNA levels and HIV viral loads were determined at baseline, at month three and at month six after initiation of a highly active antiretroviral therapy including an HIV protease inhibitor. HCV genotypes were determined using a line probe assay kit. Our results suggested that this therapy did not result in lower HCV viraemia, whatever the HCV genotypes, and probably had no effect on the outcome of chronic viral hepatitis C. As our patients were severely immunocompromised and their mean increase of CD4 cell counts was less than 50/mm(3), we cannot reach any conclusions about the impact of the improvement of immune status on the HCV-RNA load.
authors.affiliation: Laboratoire de Microbiologie, Hôpital Raymond Poicaré, Faculté de Medecine Paris-Ouest, Université Paris V, Paris, France. pmats@cc.uoa.gr
authors.forename: P
authors.initials: P
authors.lastname: Matsiota-Bernard
authors.forename: G
authors.initials: G
authors.lastname: Vrioni
authors.forename: C
authors.initials: C
authors.lastname: Onody
authors.forename: L
authors.initials: L
authors.lastname: Bernard
authors.forename: P
authors.initials: P
authors.lastname: de Truchis
authors.forename: C
authors.initials: C
authors.lastname: Peronne
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D006678:HIV / Q000187:drug effects / Q000502:physiology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects* / Q000502:physiology; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D019562:Viral Load; D014766:Viremia / Q000821:virology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir; D019438:Ritonavir